Portland, OR, June 14, 2022 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global Diabetic Retinopathy Market was estimated at $3.08 billion in 2020 and is expected to hit $10.78 billion by 2030, registering a CAGR of 13.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and varying market trends.
Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/2010
Surge in the prevalence of diabetes, rise in the geriatric population, growth in incidence of blindness due to diabetes, and increase in focus on awareness that facilitates early diagnosis to control the diseases drive the growth of the global diabetic retinopathy market. On the other hand, dearth of skilled ophthalmologists and extended approval time for drugs impede the growth to some extent. However, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of the Asia-Pacific and LAMEA regions are expected to create lucrative opportunities in the industry.
Covid-19 scenario-
- There was a steep decline in ophthalmic outpatient visits during the pandemic. DR screening was frequently postponed during the pandemic, particularly in areas with high Covid-19 community transmission. This factor impacted the global diabetic retinopathy market negatively,
- However, as the global…
